Combining four bioactive peptides is a pharmacological decision with real consequences for dosing, for stability, for interactions, and for safety and there is no published work establishing that this particular combination is additive, synergistic, redundant, or even mutually compatible in solution
In UK practice, code the clinical manifestation first (e.g., R11.0 for nausea), followed by Y42.3 (Insulin and oral hypoglycaemic drugs causing adverse effects in therapeutic use) as the secondary external cause code
Common Uses: GHK-Cu Tightens loose skin and reverses the thinning of aged skin
Although semaglutide and tirzepatide are GLP-1 agonists, tirzepatide generally works better for weight loss and obesity
If the desired research dose is 2,500mcg, the calculator indicates a draw of 0.5mL (50 units)
Storage Lyophilised (unmixed) Store long-term at -20 C (-4 F), or routinely at 2-8 C (35.6-46.4 F)